TBPMF News and Press, Tetra Bio-Pharma Inc From 03/23/20

OTTAWA, March 23, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc . (“ Tetra ” or the “ Company ”) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today would like to announce that it has ensured that all of its employees...

OTTAWA, March 06, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has engaged Alpha Bronze LLC., by its principal, Mr. Pascal Nigen, an inves...

OTTAWA, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has signed a co-development definite agreement with MAKScientific.  Thi...

CAUMZ targeting survival indications in advanced incurable cancer.  Eligible for Fast Track designation and Accelerated Approval regulatory program. 505(b)(2) NDA pathway provides significant cost savings.     OTTAWA, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma ...

QIXLEEF global market is expanded to include noncancer pain indications. Scientific approach to quality control of QIXLEEF validated by FDA.  OTTAWA, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), a leader in canna...

Tetra Bio-Pharma Inc. Announces Listing of Warrants Canada NewsWire ORLEANS, ON, Feb. 20, 2020 ORLEANS, ON , Feb. 20, 2020 /CNW Telbec/ -  Tetra Bio-Pharma Inc . (" Tetra " or the " Corporation ") (TSXV: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-based ...

A first of its kind synthetic cannabinoid medication to manage eye pain in the veterinary setting Trial expected to be completed by April 30, 2020 OTTAWA, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc ., (“ Tetra ” or the “ Company ”) a leader ...

OTTAWA, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Tetra Bio Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB: TBPMF) a leader in cannabinoid-derived drug discovery and development, is pleased to announce the appointment of Sylvain Chrétien as President of T...

Agreement secures a 2D patented printing technology that will significantly boost production capacity and reduce production costs Further protects CAUMZ™ and HCC011 with four additional manufacturing patents OTTAWA, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Tetra Bio Pharma Inc. (...

Tetra Bio-Pharma Announces Closing of Bought Deal Financing Canada NewsWire OTTAWA, Feb. 13, 2020 /NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES / OTTAWA , Feb. 13, 2020 /CNW Telbec/ - Tetra Bio-Pharma Inc. (" Te...